Molecular Basis Of Inflammatory Bowel Disease Identified By Researchers
Inflammatory bowel diseases, such as Crohn's disease and Ulcerative Colitis, severely impair the lives of more than four million people worldwide. The development of effective therapies against these diseases requires an understanding of their underlying molecular mechanisms.
Medicalnewstoday.com Sat, 17 Mar 2007 11:00:00 PDT

HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment Of Crohn's Disease
Abbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
Medicalnewstoday.com Wed, 28 Feb 2007 00:00:00 PDT

Decades-Long Study Will Help Improve Surgery For Crohn's Disease
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.Published in the journal Surgery, the study is the brainchild of Dr.
Medicalnewstoday.com Thu, 22 Feb 2007 00:00:00 PDT

AmeriHealth Expands Disease Management Program To Benefit Members With Crohn's Disease
AmeriHealth today announced it has added the gastrointestinal disorder known as Crohn's disease to its suite of disease management programs that serves more than 200,000 of its members. AmeriHealth offers the broadest array of specialized, fully accredited disease management programs in the region.
Medicalnewstoday.com Thu, 08 Feb 2007 00:00:00 PDT

Pilot Study Shows Withdrawal Drug Offers Symptom Relief To Crohn's Sufferers
Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.A team of researchers led by gastroenterologist Jill P. Smith, M.D.
Medicalnewstoday.com Tue, 06 Feb 2007 08:00:00 PDT

MedInsight(SM) Announces Clinical Trial Results Of Low-dose Naltrexone; Potential Breakthrough For Crohn's Disease Patients
The forthcoming edition of the American Journal of Gastroenterology (early release now online) reports the results of a successful clinical trial using low-dose naltrexone (LDN) to treat Crohn's disease. In 1982, Dr. Ian Zagon and Dr.
Medicalnewstoday.com Wed, 31 Jan 2007 00:00:00 PDT

Elan And Biogen Idec Submit Supplemental Biologics License Application To The Fda For The Approval Of Tysabri® As A Treatment For Crohn's Disease
Dublin, Ireland and Cambridge, MA - December 15, 2006 - Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to market TYSABRI® (natalizumab) in the U.S. as a treatment for patients with moderately to severely active Crohn's disease (CD).
Medicalnewstoday.com Tue, 02 Jan 2007 00:00:00 PDT

The Majority Of Ulcerative Colitis Patients Are Not Compliant With Medications, CCFA Survey Finds
A new, large survey supported by the Crohn's & Colitis Foundation of America (CCFA) finds that 65 percent of ulcerative colitis (UC) patients are less than fully compliant with first-line therapies to treat their disease. The findings are significant because an earlier study found that patients less than fully compliant experience five times the number of disease flare-ups.
Medicalnewstoday.com Sun, 31 Dec 2006 09:00:00 PDT

Spot The Difference: Proteasome Composition Differs In Crohn Disease And Ulcerative Colitis
Crohn disease (CD) and ulcerative colitis (UC) are the two most common inflammatory bowel diseases. Both are caused by chronic inflammation in the intestine, although the types of inflammation underlying these disorders differ -- CD is characterized by a Th1 inflammatory response and UC by a Th2 inflammatory response.
Medicalnewstoday.com Tue, 28 Nov 2006 08:00:00 PDT

Crohn's And Colitis Awareness Month 2006 - Message From Tony Clement, Minister Of Health, Canada
November is Crohn's and Colitis Awareness Month. As Minister of Health, I encourage all Canadians to use this opportunity to raise awareness about these two most common forms of inflammatory bowel disease (IBD).In Canada, approximately 144,000 people are suffering from IBD, with symptoms that include abdominal pain, cramping, fatigue and diarrhea. Canada has one of the highest rates of IBD in the world, with it primarily affecting children and young adults.
Medicalnewstoday.com Mon, 06 Nov 2006 00:00:00 PDT

Abbott's Humira® (Adalimumab) Granted FDA Priority Review For The Treatment Of Moderately To Severely Active Crohn's Disease
Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its recent supplemental Biologics License Application (sBLA) for HUMIRA® (adalimumab) as a treatment for moderately to severely active Crohn's disease.
Medicalnewstoday.com Thu, 02 Nov 2006 00:00:00 PDT


Archive